This inventor holds 6 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Immunex Corporation, Juno Therapeutics Gmbh. Active years: 2003-2020.
Location History:
- Poulsbo, WA (US) (2003 - 2007)
- Seattle, WA (US) (2006 - 2020)
Company Filing History:
Years Active: 2003-2020
Title: **Kendall M Mohler: Innovator in Engineered Cell Therapy**
Introduction
Kendall M Mohler is a notable inventor based in Seattle, WA, who has made significant contributions to the field of biotechnology and molecular therapy. With a total of six patents to his name, his innovations focus primarily on engineered cells for adoptive cell therapy, which holds promising potential for treating various types of cancers.
Latest Patents
Among his latest patents is a groundbreaking development in engineered cells for adoptive cell therapy. This patent details the creation of engineered NK cells and T cells, essential components for targeted therapies. The inventions also encompass compositions for the engineering and production of the cells, as well as methods of administration to patients. His innovative approach includes genetically engineered antigen receptors that specifically bind to various antigens, including chimeric antigen receptors (CARs) and costimulatory receptors. Notably, some versions of the engineered cells are designed to target multiple antigens and involve techniques for repressing gene products, including the disruption of genes that could potentially lead to unwanted targeting by the cells.
Career Highlights
Kendall Mohler has had a distinguished career, contributing his expertise to leading organizations such as Immunex Corporation and Juno Therapeutics GmbH. His work has not only advanced the understanding of cell therapy but also significantly enhanced therapeutic strategies available for patients.
Collaborations
Throughout his career, Mohler has collaborated with talented individuals, including Dauphine S Barone and Mary K Kennedy. These collaborations have facilitated the sharing of ideas and knowledge, further driving innovation in the development of engineered cell therapies.
Conclusion
Kendall M Mohler's contributions to the field of adoptive cell therapy have the potential to revolutionize cancer treatment and improve patient outcomes. His innovative spirit and dedication to research continue to make a positive impact on the biotechnology landscape. As he forges ahead with his work, the medical community eagerly anticipates the advancements that his inventions will bring.